AIHTA - News

Newsletter

Note: this content is only available in German.

Inhalt

Zur Druckversion...

©Mike Fouque

Announcement

Covid-19: HSS/ Horizon Scanning Living Document (v04 July 2020), Report & Appendix

The establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.

All work steps are conducted in close international (European) cooperation.

Publication: Policy Brief No. 002: http://eprints.aihta.at/1234/
Contact: Claudia Wild

More...

©videococtor

Announcement

Update PET/PET-CT evidence for need based planning in the area of oncology

Since the 1990s, the imaging technique Positron Emission Tomography (PET) has been widely used. In recent years, hardly any other technology has been examined as frequently as PET diagnostics by Health Technology Assessment Institutions. The aim of the present update was to identify oncological indications for which the use of PET/PET-CT is recommended or explicitly not recommended by relevant societies and in evidence-based guidelines. A total of 37 evidence-based guidelines were identified regarding the use of PET for oncological indications. In the case of four oncological indications, a positive recommendation regarding the use of PET could be identified. In contrast, for eight indications a restricted use was recommended. No evidence in favour of PET examinations was identified for six indications, and for seven indication there was no, too little or inconclusive (controversial) evidence available. Just in a scarcity of instances an overall recommendations for the application of PET as a primary or standard diagnostic procedure was issued in the update 2020. In general, the present summarised evidence of guidelines can support appropriate health care service provision in Austrian hospitals.

Publication: AIHTA Policy Brief No.: 003: http://eprints.aihta.at/1249/
Contact: Nicole Grössmann

More...

©Juan Gärtner

Announcement

Horizon Scanning in Oncology - Fact Sheets

We are pleased to introduce our four new HSO Fact Sheets.

Fact Sheet No. 11 (Mai 2020)
Maintenance olaparib (Lynparza®) for the treatment of patients with germline BRCA-mutated metastatic pancreatic cancer

Fact Sheet No. 12 (Mai 2020)
Alpelisib (Piqray®) plus fulvestrant for PIK3CA-mutated, hormone receptor–positive advanced breast cancer

Fact Sheet No. 13 (Mai 2020)
Entrectinib (Rozlytrek®) for the treatment of patients whose solid tumours have a NTRK gene fusion, or patients with ROS1-positive advanced NSCLC

More...

©stock.adobe.com

Project / Psychological & psychiatric interventions

Effectiveness of music therapy

Project leaders: Claudia Wild

Project team: Lucia Gassner, Julia Mayer-Ferbas

Laufzeit: Juni bis Oktober 2020
Sprache: Englisch mit deutscher Zusammenfassung

Publication: HTA Projektbericht No. 133: http://eprints.aihta.at/1280/

More...

©Mike Fouque

Announcement

Covid-19: HSS/ Horizon Scanning Living Document (v03 June 2020)

The establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.

All work steps are conducted in close international (European) cooperation.

Publication: Policy Brief No. 002: http://eprints.aihta.at/1234/
Contact: Claudia Wild

More...

©Stefan Yang

Announcement

Proton and carbon ion therapy – an update on indications

Worldwide, 82 particle therapy facilities are currently in clinical operation; further 37 centers are under construction or in planning. This means that the number of centres worldwide has more than doubled since 2013. In Europe alone, 27 centres are currently operational (2013: 14). With such a large number of treatment centers, it should be assumed that the underlying clinical evidence on patient benefit is convincing. The update of the LBI-HTA report 2013 has the task to give an overview of secured indications as well as indications that are only recommended under clinical research. Only a hand search for HTA reviews and systematic reviews was conducted. The identified reviews articulate in unison that the available - mostly retrospective - studies are of low quality and insufficient to make conclusive statements on the added value of proton or carbon ion therapy. Only a few indications are recommended for proton or carbon ion therapy (chordomas and chondrosarcomas, uveamelanoma, pediatric tumors in the base of the skull, brain and head and neck tumors) to avoid secondary tumors. Further indications, with curative intention and non-metastatic, are only recommended under conditions of prospective clinical studies.

Publication: AIHTA Policy Brief No.: 004: http://eprints.aihta.at/1245/
Contact: Claudia Wild

More...